BRAF and cancer: We first developed assay to detect common BRAF V600 mutations, i.e. V600E (c.1799T>A or c.1799_1800delTGinsAA) and V600K (c.1798_1799delGTinsAA), which indicate a response to cancer treatment by BRAF inhibitors [13–16].